Middle East & Africa NGS Market (2025-2032)
The Middle East & Africa NGS Market was valued at $155 million in 2024. This market is expected to reach $356.5 million by 2032, from an estimated $170.7 million in 2025, at a CAGR of 11.1% during the forecast period 2025-2032. Middle East & Africa NGS Market Size & Forecast Next Generation Sequencing
- Published
- Feb 2024
- Pages
- 150
- Format
- PDF + Excel
- Report ID
- MR-1103
- Base year
- 2024
- 2024 · BASELINE
- $155.0M
- 2032
- $356.5M
- CAGR 2025–2032
- 11.1%
2024 baseline · 2025–2032 forecast at 11.1% CAGR · hover a bar for the value
Key highlights
Consumables Segment to Account for the Largest Share of the Market in 2025
Targeted Genome Sequencing Segment to Account for the Largest Share of the Market in 2025
Sequencing by Synthesis Segment to Account for the Largest Share of the Market in 2025
Research Applications Segment to Account for the Largest Share of the Market in 2025
Pharmaceutical & Biotechnology Companies Segment to Account for the Largest Share of the Middle East & Africa NGS Market in 2025
Saudi Arabia to Account for the Largest Market Share in 2025
Report summary
| Particulars | Details |
|---|---|
| Number of Pages | ~150 |
| Format | |
| Forecast Period | 2025-2032 |
| Base Year | 2024 |
| CAGR | 11.1% |
| Estimated Market Size (Value) | $ 356.5 million by 2032 |
| Segments Covered | By Offering · Consumables · Sample Preparation Consumables · DNA Extraction and Amplification · Library Preparation & Target Enrichment · Quality Control · Other Consumables · NGS Platforms/Instruments · Software · Services · (Note: Other consumables include vials, pipettes, containers, trays, sequencing reagents, flow cells, and tubes.) · By Sequencing Type · Targeted Genome Sequencing · Whole Genome Sequencing · Whole Exome Sequencing · Other Sequencing Types · (Note: Other sequencing types include degradome sequencing, chromatin immunoprecipitation (ChIP) sequencing, and methylation sequencing.) · By Technology · Sequencing by Synthesis · Ion Semiconductor Sequencing · Single-molecule Real-time Sequencing (SMRT) · Nanopore Sequencing · DNA Nanoball Sequencing · By Application · Research Applications · Drug Discovery · Agriculture & Animal Research · Other Research Applications · Clinical Applications · Reproductive Health Diagnosis · Oncology · Infectious Diseases · Other Clinical Applications · (Note: Other research applications include food microbiology, microbiota analysis in the beverage industry, and environmental studies, and other clinical applications include the detection of genetic aberrations in neurological disorders, rare diseases, metabolic and immune disorders, and food-borne illnesses.) · By End User · Pharmaceutical & Biotechnology Companies · Hospitals and Diagnostic Laboratories · Academic Institutes & Research Centers · Other End Users · (Note: Other end users include forensic laboratories & security agencies, food & beverage companies, and agriculture companies.) |
| Countries Covered | Middle East & Africa (United Arab Emirates, Saudi Arabia, Egypt, South Africa, Qatar, and Rest of Middle East & Africa) |
| Key Companies | Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), PerkinElmer, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), 10X Genomics, Inc. (U.S.), and Pacific Biosciences of California Inc. (U.S.). |
Report overview
Segments covered: offering, application, technology. Regions: Middle East & Africa.
Next Generation Sequencing (NGS) is a genome sequencing technology usually used for research purposes and applied in clinical diagnostics. NGS determines the order of nucleotides in the entire genomes or targeted regions of DNA or RNA. It is used for various research and clinical applications such as disease diagnosis, prognosis, therapeutic decisions, follow-up of patients, drug discovery, biomarker research, and environmental testing. Also, its massive parallel sequencing capacity offers new opportunities for personalized or precision medicine.
The growth of the Middle East & Africa NGS market can be attributed to various factors, including the surge in genome sequencing programs, technological advancements in sequencing procedures, decreasing costs of genome sequencing, and a rise in cancer prevalence, and the expanding applications of NGS in cancer treatment and research. However, the high costs of NGS systems and consumables and the availability of alternative technologies restrain the market's growth.
The rising adoption of bioinformatics and genomic data management solutions, as well as collaborations and partnerships to support next-generation sequencing, are expected to create market growth opportunities. However, a lack of skilled professionals and a lack of standardization pose a significant challenge to the market's growth.
Market dynamics
5 factors across 2 forcesAccording to The National (a local daily newspaper),
in March 2024, the UAE President launched the National genome strategy. This launch aims to map the DNA of every citizen to provide personalized care to every citizen in the country.
the Qatar Genome Program (QGP),
launched in 2015, completed the sequencing of 25,000 whole genomes in 2021 and is now in its largest “Phase 3”, with the aim to sequence 100,000 genomes by 2025.
In October 2020,
the Africa Centers for Disease Control and Prevention and the African Union Commission launched an initiative to expand genomics-based public health pathogen surveillance. This pathogen genomics initiative was launched with an investment of USD 100 million from its partners to expand NGS capabilities in the region.
Table of contents
13 chapters · 97 sections · 150 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Offering | Consumables | — |
| By Sequencing Type | Targeted Genome Sequencing | — |
| By Technology | Sequencing by Synthesis | — |
| By Application | Research Applications | — |
| By End User | Pharmaceutical & Biotechnology Companies | — |
By Offering
- Consumables Segment to Account for the Largest Share of the Market in 2025
- The consumables segment is expected to account for the largest share of the Middle East & Africa NGS market.
- The increasing use of sequencing reagents and kits for diagnostic procedures has majorly attributed to the large share of this segment in the Middle East & Africa NGS market.
- Additionally, factors such as increasing genome mapping projects, rising preference for NGS-based diagnostic tests, and increasing awareness about the advantages of NGS for diagnostic and research purposes are supporting the growth of the segment.
By Sequencing Type
- Targeted Genome Sequencing Segment to Account for the Largest Share of the Market in 2025
- The targeted genome sequencing segment is expected to account for the largest share of the Middle East & Africa NGS market.
- Targeted genome sequencing significantly reduces the cost per sample over whole genome shotgun sequencing by enabling sequencing of only the desired regions of a genome.
- Furthermore, the early success of targeted sequencing methods has created a rapidly growing demand for targeted sequencing in areas such as cancer, human genetic disease, and the validation of genome-wide association studies.
- These factors have increased the adoption of targeted genome sequencing, contributing to the large market share of this segment.
By Technology
- Sequencing by Synthesis Segment to Account for the Largest Share of the Market in 2025
- The sequencing by synthesis segment is expected to account for the largest share of the Middle East & Africa NGS market.
- The large share of this segment is primarily attributed to the high accuracy of this technology in DNA sequencing, its highest yield of error-free throughput, and the increasing incorporation of this technology in NGS products.
By Application
- Research Applications Segment to Account for the Largest Share of the Market in 2025
- The research applications segment is expected to account for the largest share of the Middle East & Africa NGS market.
- The large market share of this segment is attributed to the rising adoption of sequencing-based tests in laboratories, growing research activities by pharmaceutical & biotechnology companies, increasing applications of NGS, growing demand for personalized medicines, and increasing availability of NGS instruments at lower costs are some of the major factors attributed to the large share of this segment in the NGS market.
By End User
- Pharmaceutical & Biotechnology Companies Segment to Account for the Largest Share of the Middle East & Africa NGS Market in 2025
- The pharmaceutical & biotechnology companies’ segment is expected to account for the largest share of the Middle East & Africa NGS market.
- The large market share of this segment is attributed to factors such as the increasing adoption of advanced technologies for research purposes, increasing research for drug discovery with widening NGS applications, and the rising incidence of chronic diseases.
- For instance, according to GLOBOCAN, in 2022, 5,526 people were diagnosed with cancer in the United Arab Emirates.
- This number is projected to reach 7, 328 by 2032.
- Further, in 2022, 28,113 people were diagnosed with cancer in Saudi Arabia.
- This number is projected to reach 39, 900 by 2032.
Geographic analysis
Middle East & Africa
Largest shareIn 2025, Saudi Arabia is expected to account for the largest share of the Middle East & Africa NGS market. Saudi Arabia’s significant market share can be attributed to the growing adoption of NGS technology among healthcare professionals for the treatment of diseases and an increasing number of sequencing projects such as the Saudi Human Genome Programme, The Saudi Biobank, and Majeen. Saudi Arabia to Account for the Largest Market Share in 2025
Competitive landscape
The report includes a competitive landscape based on an extensive assessment of the key growth strategies adopted by leading market players over the past three to four years. The key players profiled in the Middle East & Africa NGS market report are Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), PerkinElmer, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), 10X Genomics, Inc. (U.S.), and Pacific Biosciences of California Inc. (U.S.).
- Thermo Fisher Scientific Inc. (U.S.)
- Illumina, Inc. (U.S.)
- Qiagen N.V. · Netherlands
- F. Hoffmann-La Roche Ltd · Switzerland
- PerkinElmer, Inc. (U.S.)
- Agilent Technologies, Inc. (U.S.)
- Danaher Corporation (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- Oxford Nanopore Technologies Plc. (U.K.)
- 10X Genomics, Inc. (U.S.)
- Pacific Biosciences of California Inc. (U.S.)
Frequently asked questions
This study offers a detailed assessment of the Middle East & Africa NGS market, including the market sizes and forecasts for various segmentations like offering, sequencing type, technology, application, and end user. This report also involves the value analysis of various segments and sub-segments of NGS at the country level.
Cite this report
Meticulous Research. (2024). Middle East & Africa NGS Market - Opportunity Analysis And Industry Forecast (2025-2032) (Report No. MR-1103). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/reports/middle-east-and-africa-ngs-market-5786